Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity

Dora L. Vallejo-Ardila; Theodora Fifis; Louise M. Burrell; Katrina Walsh; Christopher Christophi

doi:10.18632/oncotarget.26174

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity

Dora L. Vallejo-Ardila _, Theodora Fifis, Louise M. Burrell, Katrina Walsh and Christopher Christophi

PDF | HTML | How to cite | Press Release

Oncotarget. 2018; 9:35500-35511. https://doi.org/10.18632/oncotarget.26174

Metrics: PDF 1708 views | HTML 3297 views | ?

Abstract

Dora L. Vallejo-Ardila1, Theodora Fifis1, Louise M. Burrell2,3, Katrina Walsh1 and Christopher Christophi1

1Department of Surgery, Austin Health, University of Melbourne, Melbourne,VIC 3084, Australia

2Department of Medicine, Austin Health, University of Melbourne, Melbourne, VIC 3084, Australia

3Department of Cardiology, Austin Health, University of Melbourne, Melbourne, VIC 3084, Australia

Correspondence to:

Dora L. Vallejo-Ardila, email: [email protected]

Keywords: renin-angiotensin system; tumor microenvironment; anti-tumor immunity; kallikrein kinin system

Received: June 26, 2018 Accepted: September 08, 2018 Published: October 26, 2018

ABSTRACT

Renin-angiotensin system inhibitors (RASi) have shown potential anti-tumor effects that may have a significant impact in cancer therapy. The components of the renin-angiotensin system (RAS) including both, conventional and alternative axis, appear to have contradictory effects on tumor biology. The mechanisms by which RASi impair tumor growth extend beyond their function of modulating tumor vasculature. The major focus of this review is to analyze other mechanisms by which RASi reprogram the tumor immune microenvironment. These involve impairing hypoxia and acidosis within the tumor stroma, regulating inflammatory signaling pathways and oxidative stress, modulating the function of the non-cellular components and immune cells, and regulating the cross-talk between kalli krein kinin system and RAS.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26174

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity

Abstract